Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ELOVL6 | Q9H5J4 | 5/20 | 0.40 |
| ▸ | MMP13 | P45452 | 3/20 | 0.40 |
| ▸ | MMP8 | P22894 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27095423 | 0.80 | HTR2A (0.45) | HTR2AMAPTELOVL6MMP13MMP8 | |
| SCHEMBL2048495 | 0.76 | HTR2A (0.59) | HTR2AMAPTMMP13MMP8MMP1 | |
| SCHEMBL24483696 | 0.76 | MMP13 (0.40) | HTR2AMAPTELOVL6MMP13MMP8 | |
| SCHEMBL11120903 | 0.75 | HTR2A (0.51) | HTR2AMAPTELOVL6KCNH2HTR2C | |
| SCHEMBL24483535 | 0.74 | POLB (0.41) | MAPTACHEALDH1A1KDM4EMEN1 | |
| SCHEMBL24483976 | 0.74 | POLB (0.41) | MAPTACHEALDH1A1KDM4EMEN1 | |
| SCHEMBL9727592 | 0.73 | HTR2A (0.49) | HTR2AMAPTELOVL6MMP13MMP8 | |
| SCHEMBL16863988 | 0.72 | HTR2A (0.56) | HTR2AMAPTELOVL6KCNH2HTR2C | |
| SCHEMBL23720121 | 0.71 | L3MBTL1 (0.46) | HTR2AMAPTMMP8ACHEALDH1A1 | |
| Cyanide SCHEMBL27638463 | 0.71 | HTR2A (0.54) | HTR2AMAPTMMP13MMP8MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169580-A1 | METHODS OF CARBON-CARBON BOND FRAGMENTATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169580-A1 | METHODS OF CARBON-CARBON BOND FRAGMENTATION | CYCS, COX6C, COXFA4L2 | HTR2A 4430/4885MAPT 4085/4885ELOVL6 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.